Navigation Links
Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development

MORRISVILLE, N.C., May 20 /PRNewswire/ --Asymchem Laboratories, Inc., a leading research-based contract manufacturer of API's, intermediates and Drug Products to the pharmaceutical industry, with sites in the U.S. and China, is pleased to announce the recent addition of Dr. Chris Huber as Director of Chemical Development.

Dr. Huber brings to the table over 15 years experience in the pharmaceutical industry (early and late stage), developing process technology for API manufacturing of small molecules. Prior to Asymchem, Dr. Huber directed early phase projects for API manufacturing at Achaogen Inc. and Arena Pharmaceuticals. Much of his career was spent in Pfizer and legacy companies in process chemistry, with focus on optimization, characterization and validation of Phase 3 processes in preparation for commercial manufacturing of API.

As Director of Chemical Development, Dr. Huber will help expand and strengthen Asymchem's pilot scale-up, tech transfers and production efforts into commercial manufacturing. He will report directly to Dr. Jim Gage, VP of Chemical Development.

"I am very pleased to have Dr. Huber on board to help expand and strengthen Asymchem's already well-established large scale manufacturing services," states Dr Hao Hong, CEO of Asymchem. "With his broad experience in the pharmaceutical industry and proven track record of API manufacturing, I am confident that our commercial capabilities will be further strengthened and solidified."

Dr. Huber received his B.S. and M.S. at the Universitat Regensburg , Germany under the supervision of Professors Dr. Henri Brunner, Dr. Jurgen Sauer and Dr. Josef Barthel. He earned his Ph.D. in Organic Chemistry and Catalysis from the Universitat Regensburg, Germany with Professor Dr. Henri Brunner. He did his post doc at Purdue University, Indiana under Professor Thomas Bein on the development of supported organometallic catalysts with application in organic synthesis.

Asymchem Laboratories is a leading research-based contract manufacturer specialized in the development and compliant manufacturing (Contract Research and Manufacturing Services) of API's and Drug Products serving the pharmaceutical industry. With a 14yr track record, Asymchem is committed to the highest level of quality and excellence in the integrated CMC services arena. For further information, please visit the Asymchem website at

SOURCE Asymchem Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Fina Technologies Names Spotfire Founder Christopher Ahlberg to Board of Directors
2. Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise
3. VITAS Innovative Hospice Care(R) Names Christopher Rieder Senior Vice President and Chief Information Officer
4. Christopher and Dana Reeve Foundation Response to FDA Clearance of Gerons Clinical Trial
5. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
6. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
7. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
8. Christine Poon Will Keynote MichBio Expo
9. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
10. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
11. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
Post Your Comments:
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
(Date:10/27/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leader ... adopted the Synaptics ® ClearPad ® Series ... newest flagship smartphones, the Nexus 5X by LG and ... --> --> Synaptics works closely with ... in the joint development of next generation technologies. Together, ...
(Date:10/26/2015)...  Delta ID Inc., a company focused on bringing ... devices, announced its ActiveIRIS® technology powers the iris recognition ... by NTT DOCOMO, INC in Japan ... to include iris recognition technology, after a very successful ... May 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):